Sanofi Agreement was Kymera Therapeutics’s largest revenue line in fiscal 2025, bringing in $33.60M of $39.20M (86%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2019 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Sanofi Agreement | $70.20M | $47.10M | $33.60M | ||
| Vertex Agreement | $8.40M | — | — | ||
| Gilead Agreement | — | — | $5.60M | ||
| Total | $78.60M | $47.10M | $39.20M |
Kymera Therapeutics brought in $39.20M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Kymera Therapeutics regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $47.10M. Sanofi Agreement was the largest at $33.60M (85.7%), ahead of Gilead Agreement at $5.60M (14.3%).
Kymera Therapeutics began breaking out Gilead Agreement in fiscal 2025, when it brought in $5.60M. Kymera Therapeutics stopped reporting Vertex Agreement as a separate revenue line after fiscal 2023, when it brought in $8.40M.
Kymera Therapeutics (KYMR) reports its revenue by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, Sanofi Agreement was its largest revenue line, bringing in $33.60M (85.7% of the total), followed by Gilead Agreement at $5.60M (14.3%).
Sanofi Agreement was Kymera Therapeutics' largest revenue line in fiscal 2025, bringing in $33.60M, or 85.7% of the $39.20M total across its two revenue lines.
Every figure comes from Kymera Therapeutics' annual financial filings, as reported. Each line keeps the name Kymera Therapeutics gives it, and years follow its fiscal calendar.
Kymera Therapeutics' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.